Ignite Creation Date:
2024-05-06 @ 6:32 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05692050
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2023-02-03
First Post:
2023-01-13
Brief Title:
Expanded Access to Epcoritamab
Sponsor:
AbbVie
Organization:
AbbVie
Study Overview
Official Title:
Expanded Access to Epcoritamab
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an expanded access program EAP for eligible participants This program is designed to provide access to epcoritamab prior to approval by the local regulatory agency Availability will depend on territory eligibility A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patients medical history and program eligibility criteria
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None